October 2, 2025 8:08am

After rising share pricing from a traumatic Wednesday; the cell and gene therapy sector wobbles

I also hate to be negative or a hardened contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but, I am mostly EARLY!”

Pre-open Signals: 6 Positive, 2 Sell into Strength and 3 Negative Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!


As a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends styles setting forth my difference re: retail, trading and multiple investor categories

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Wednesday night’s … RMi Closing Bell: Resilience … https://www.regmedinvestors.com/articles/14132

 

Thursday: The pre-open Dow futures are DOWN -0.08% or (-36 points), the S&P futures are UP +0.23% or (+16 points) and the Nasdaq futures are UP +0.52% or (+129 points)

  • Stock futures are mixed Thursday, 10/2
  • European stocks moved higher,
  • Asia Pacific markets were higher

 

Henry’omics: We need to more than consider the markets …environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed UP +43.21 points or +0.09%, the S&P closed UP +22.74 points or +0.34% while the Nasdaq closed UP +95.148 points or +0.422%
  • Tuesday: The Dow closed UP +81.82 points or +0.18%, the S&P closed UP +27.25 points or +0.41% while the Nasdaq closed UP +68.855 points or +0.31%
  • Monday: The Dow closed UP +68.78 points or +0.15%, the S&P closed UP +17.51 points or +0.26% while the Nasdaq closed UP +107.085 points or +0.48%
  • Last week, the Dow has shed 0.8%, the S&P 500 is down nearly 0.9% and the Nasdaq has lost about 1.1%
  • Last month and Q3’s numbers, the S&P 500 Q is up 7% and the month -4.2%, the Nasdaq’s Q is up +11% and the month +5% while the Dow’s Q is up +5% and the month +1%

Economic Data Docket: delayed

 

Q4 – 1s positive session

  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • October begins  with a government shutdown and fewer econs… along with the usual ups, downs and just plain unce-rtainties

Some indications in MY view:

IQV Holdings (IQV) closed up +$13.85 after Tuesday’s +$9.18 and Monday’s +$1.17 with a negative -$0.29 or -0.14% pre-open

Vertex (VRTX) closed up +$12.57 after Tuesday’s -$3.67 after Monday’s +$9.58 with a negative -0.19 or -0.05% pre-open

Alnylam Pharmaceuticals (ALNY) closed +$4.65 after Tuesday’s +$8.51 after Monday’s +$1.09 with a positive +$2.35 or +0.51% pre-open – Sell into Strength

BioNTech (BNTX) closed up +$3.59 after Tuesday’s +$0.52 with a positive +$0.37 or +0.36% pre-open

Lenz Therapeutics (LENZ closed +$2.47 after Tuesday’s +$1.69 after Monday’s +$2.86 with a positive +$1.01 or +2.06% pre-open

Moderna (MRNA) closed up +$1.77 after Tuesday’s +$0.52) with a positive +$0.42 or +1.52 pre-open

Intellia Therapeutics (NTLA0 closed up +$1.49 with a positive +$0.62 or +3.30% pre-open

CRISPR Therapeutics (CRSP) closed up +$1.35 after Tuesday’s +$1.04 after Monday’s +$2.10 with a positive +$0.84 or +1.27% pre-open

Capricor Therapeutics (CAPR +$0.61 after Tuesday’s -$0.20 with a positive +$0.02 pre-open - Sell into Strength

uniQure NV (QURE) closed down -$3.38 after Tuesday’s -$1.03 and Monday’s +$5.09 with a positive +$0.76 or +1.38% pre-open

 

 

The BOTTOM LINE: I can’t seem to let go of this quote, “It’s always darkest before the pitch dark”

  • The cell and gene therapy sector ended seeing a few too many fits and starts, so …

Reiterating, “What to Do Now: The stock market rally continues to do well, but … with the major indexes all near record highs … “uncle algo and his electronic trading dwarfs” are smelling some profits!”

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

October: understand the new “flow” …

  • 10/1 – Wednesday closed positive with 26 positive, 14 negative and 0 flat
  • 9/29 – Monday closed positive with 33 positive, 5 negative and 2 flats

Last week:

  • 9/26 – Friday closed positive with 29 positive, 9 negative and 2 flats
  • 9/25 - Thursday closed negative with 8 positive, 30 negative and 2 flat
  • 9/24 – Wednesday closed positive with 28 positive, 11 negative and 1 flat
  • 9/23 – Tuesday closed negative with 7 positive, 32 negative and 1 flat
  • 9/22 – Monday closed positive with 31 positive, 9 negative and 0 flat

 

Q3 Earnings are in the front-view mirror; we are about to start again …!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.